Articles On Recce Pharmaceuticals (ASX:RCE)

Whilst the ASX200 has slipped .6 of a per cent, that performance is considerably better than futures suggested.  Real estate and health care are the key drags on the market today, losing almost 1 and a half per cent each, while consumer...

Recce Pharmaceuticals (RCE) completes dosing its male and female subjects in its phase I/II UTI clinical trial with Scientia Research The trial evaluates R327 anti-infective at faster infusion rates of 30 minutes at a dosage of 3000mg, w...

Treatment for infectious diseases continues to pose a significant threat to populations worldwide, with the effectiveness of many anti-infective medications lost to antimicrobial resistance (AMR).  However, in this current era where conc...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

Recce Pharmaceuticals (ASX: RCE), a company developing a new class of synthetic antibiotics, is raising $11 million to boost its research program, bolster manufacturing capabilities and expand further into the US. The Sydney-based company,...

The ASX200 gradually climbed today to gain close to half a per cent. Financials registered the highest gains, up nearly 1.3 per cent With that, the big four banks NAB, CBA, Westpac and ANZ all gained around a per cent. Healthcare, on...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from a trading halt and crashed deep into the red. In afternoon trade, the pharmaceutical company's shares are down 26% to 48 cents. Why is the Recce Pharmaceuticals share p...

Recce Pharmaceuticals (RCE) is raising up to $11 million through a strongly supported placement and entitlement offer The placement comprises the issuance of 18.2 million new shares at 44 cents each Funds will be used toward further t...

ASX 200 closes about 0.3% lower, down well over 2.2% for the week. Materials and Consumer discretionary weigh, Healthcare rises. Small caps led by Oliver’s Real Foods, which has leapt mightily despite having no fresh news.   The Aussie...

The ASX200 has traded down about point four of a per cent this morning.  Sector performances varied, with utilities leading with a gain of .7 per cent, while materials stocks shed just shy of a per cent.  Mining giants BHP, FMG and Ri...

The Australian stock market has dropped more than three-quarters of a per cent in the first hours of trade. Energy has been the only sector in the green after oil-producing nations vowed to continue limiting supply. Energy has been up we...

Cannabis biotech Bod surges after good clinical trial results Imricor granted US$1.15m award in the US Recce issued trademark registration in Vietnam   Bod Science’s CBD-based insomnia drug beats placebo Cannabis focused biotech Bod Scien...

Recce Pharmaceuticals (RCE) secures trademark registration for RECCE in Vietnam It was issued by the Intellectual Property Office of Vietnam Vietnam’s pharmaceutical market is expected to reach A$25.2 billion in value by 2026 Recce...

Recce Pharmaceuticals (RCE) reports its R327 gel product saw one elderly patient avoid amputation of an infected toe The company also cited two other patients with antibiotic-resistant infections who both responded well to the treatment...

Recce Pharmaceuticals (RCE) receives the green light to advance to the next cohort of its anti-infective R327 UTI phase I/II clinical trial The Independent Safety Committee agrees R327 is safe and well-tolerated at IV dosages of 2500mg,...

Recce Pharmaceuticals (RCE) kicks off its phase I/II diabetic foot infection trial The company will apply its flagship R327 anti-infective as a topical treatment RCE is using R327 to treat UTIs, burns patients, and now those with DF...

Recce Pharmaceuticals’ (RCE) phase I/II R327 topical burn wound clinical trial successfully treats bacterial infections in all patients to date Clinicians report a visible reduction in bacterial infections within the first 24 hours of us...

The ASX has seen a slight lift, up almost 0.2 per cent in early afternoon trade. Materials are leading the sectors up around half a per cent, good news for those attending Diggers & Dealers in Kalgoorlie. The sector is followed cl...

Mesoblast Ltd (ASX: MSB) shares are sliding again on Tuesday. Shares in the ASX biotech company are down 3.7% at time of writing to 40 cents a share. That puts Mesoblast shares down a painful 55% since the opening bell rang on 3 January....

Recce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) program Race Oncology unveils new corporate strategy   Recce surges on anecdotal results Recce Pharma (ASX:RCE) raced higher by more than 20%...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Recce Pharmaceuticals (RCE) RCE 327 Gel shows promise in treating multiple antibiotic-resistant infections under the TGA SAS Category A The gel achieved a >99.99 per cent reduction against MRSA in an ex-vivo burn wound study Clinic...

Recce Pharmaceuticals (RCE) is granted a new patent in Australia protecting its in-house R327 and R529 anti-infectives Recce is primarily focused on R327 which is the subject of an ongoing trial showing superior results so far compared...

The ASX200 closed 0.7 per cent down to finish the week. Only energy, IT and utilities sectors ended the week afloat, and then only just. Uncertainties around interest rates took a toll, exacerbated by fading hopes around China injecti...

The ASX 200 has been trading down almost a per cent  – energy’s the only sector making gains and only just. Materials has been the worst performer shedding more than 1.8 per cent. Ahead of the RBA’s interest decision next week, the Bu...

Recce Pharmaceuticals’ (RCE) phase I/II trial partner has wrapped up the second-stage dosages of its ongoing trial A third cohort of patients is now being recruited ahead of schedule The company’s flagship anti-infective UTI product...

Recce Pharmaceutical’s (RCE) flagship anti-infective UTI treatment R327 was proven to be safe last week The company’s phase I/II trial is now accelerating ahead of schedule with the help of NSW-based partner Scientia Recce expects d...

The ASX is trading well today up nearly half a per cent with only the materials and communications sectors taking a dip. ASX200 giant Woodside Energy (WDS) is up 1.5 per cent after releasing its June quarterly report. Its full-year produ...

Recce Pharmaceuticals (RCE) announces “positive” results from its completed phase one study of anti-infective R327 The trial doses R327 from 50mg to 6000mg and marks the first-in-human study to display safe and well-tolerated treatment w...

The Reserve Bank Governor Phillip Lowe would like to continue in the role he’s held since 2016. Speaking at the Australian Conference of Economists in Brisbane today, he recognised that Treasurer Jim Chalmers will reveal his decision on...

Recce Pharmaceuticals (RCE) receives $801,604 from Radium Capital as part of Recce’s future research and development tax incentive The company is now over $3 million in rebates for its R&D activities through FY23 RCE CEO James Gr...

Recce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R327 at faster infusion rates has successfully dosed its first cohort of male and female subjects.

The ASX 200 has dipped just a little in early trade. Exploration company Dreadnought Resources (DRE) is up more than five per cent after defining fresh rare earths’ zones at its Mangaroon project in Western Australia. A 24-hole, 4000-...

Recce Pharmaceuticals is developing an IV-administered treatment for Urinary Tract Infections (UTIs) Its RECCE 327 formula has been observed to rapidly kill E. coli bacteria in both male and female patients The company recently woun...

Recce Pharmaceuticals (RCE) gains approval from the Human Research Ethics Committee to expand its phase I/II trial of R327 to treat UTIs The trial is assessing faster administration rates with Scientia Clinical Research facilitating the...

The ASX is tracking up in midday trade, with mining giants and the big four banks all in positive territory. In the materials space, Leo Lithium (LLL) has jumped 17.6 per cent after China’s largest lithium producer, Ganfeng, committed to...

Recce Pharmaceuticals (RCE) appoints outpatient nurses from leading healthcare provider Ascott The nurses, trained in R327 DFI treatment, will broaden the company’s diabetic foot infection (DFI) trial patient population RCE’s phase on...

The ASX opened on a higher note today, with real estate, energy, and banking stocks contributing to the overall gain. The materials sector also led the pack, climbing nearly two per cent before lunchtime. Red 5 (RED) was amongst the comp...

Recce Pharmaceuticals (RCE) secures sponsorship from the West Australian government to attend BIO Korea 2023 RCE has been selected as one of three WA companies to attend the bio-health industry conference in Seoul this week The govern...

Developing a drug that is safe and effective for public use is no easy feat. It requires years of clinical trials, extensive research, and a significant financial investment before it can be sold on the shelves of your local pharmacy. Ma...

Recce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phase I/II intravenous clinical trial of its lead R327 drug As part of the trial, RCE will assess intravenous doses of R327 at infusion rates...

Recce Pharmaceuticals (RCE) last year confirmed the safety of its R327 antibiotics treatment for human use, and now it’s working to confirm the treatment’s efficacy in the patient population. R327 is the world’s first breakthrough antibi...

Recce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives The patent covers the “Process for Preparation of Biological...

The ASX is tipped to open slightly higher on Tuesday following the slight rise to ASX futures when they traded during New York hours on Good Friday. That said, it is shaping up to be a big week for Wall Street, with key price data and qu...

Recce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued notification of intent to grant the first of its new 'Patent Family 4' for its anti-infectives 'Process for Preparation of Biologically Activ...

The ASX 200 will open slightly higher on Tuesday Tesla to expand in China to produce mega batteries Aussie Brian Hood sues ChatGPT for defamation   The ASX is set for a modest opening on Tuesday after a mixed session in New York. At 8am A...

Energy stocks have surged in early trade after OPEC’s controversial move to cut oil production by one million barrels per day. But it’s been a boost to companies in the sector, which has risen around 1.5 per cent. TMK Energy shares al...

Recce Pharmaceuticals (RCE) pockets a further $973,144 from Radium Capital as part of Recce’s future research and development tax incentive The payment from Radium represents an accountant-verified proportion of Recce’s December to Febru...

Recce Pharmaceuticals (ASX:RCE) has received further non-dilutive funds from Radium Capital of almost $1 million as an advance payment of its R&D Tax Incentive rebate from the Australian government.

Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs) The phase one and two intravenous clinical trial will assess RCE’s le...